Ligand Pharmaceuticals Incorporated provided earnings guidance for the year 2024. For the year, the company expects total revenue of $130 million to $142 million, comprised of $90 million to $95 million from royalties, $25 million to $27 million from sales of Captisol and $15 million to $20 million from contract revenue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.57 USD | +0.28% | -2.62% | -1.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.19% | 1.27B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Provides Earnings Guidance for the Year 2024